1 completed, 1 recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Kasabach Merritt Phenomenon: new trials by email Literature Review of Kasabach Merritt Phenomenon trials Research Report on Kasabach Merritt Phenomenon
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP Sirolimus (RAPAMUNE) - Kaposiform Hemangioendothelioma (KHE), Kasabach Merritt Phenomenon | Phase 2 / Phase 3 | Recruiting | Yi Ji | 76 | 2026-06-16 | 2026-06-18 |
| Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma Sirolimus, Prednisolone - Kaposiform Hemangioendothelioma, Kasabach Merritt Phenomenon | Phase 2 | Completed | West China Hospital | 30 | 2017-06-01 | 2022-04-21 |
Kaposiform Hemangioendothelioma (2) · Kasabach-Merritt Syndrome (2)
Blood Platelet Disorders (2) · Cytopenia (2) · Hemangioma (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Vascular Tissue (2) · Thrombocytopenia (2)
Sirolimus (2) · Prednisolone (1)
West China Hospital (1) · Yi Ji (1)
China (2)
Jiangyuan Zhou, MD (1) · Yi Ji (1) · Yi Ji, MD, PhD (1)
PMID 35030255, PMID 22871490, PMID 28486787, PMID 31489702, PMID 32014025, PMID 33580918, PMID 34082006, PMID 34273457, PMID 3691614, PMID 3936944, PMID 39831682, PMID 40107509, PMID 41831614